Monitoring the acute phase response in non-immediate allergic drug reactions

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 4, 2006, Pages 249-257

  Mayorga, Cristobalina ^a   Pena, Rebeca R ^a   Blanca López, Natalia ^a   López, Soledad ^a   Martin, Enrique ^a   Torres, Maria Jose ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Drug; Immunological response; Monitoring; Nonimmediate reaction

Indexed keywords

BLOOD DISEASE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; ACUTE PHASE RESPONSE; BLOOD; DRUG EFFECT; DRUG ERUPTION; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METHODOLOGY; SKIN;

ACUTE-PHASE REACTION; DRUG ERUPTIONS; HUMANS; MONITORING, IMMUNOLOGIC; SKIN;

EID: 33748458700     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000235897.72429.4a     Document Type: Review

References (68)

1. Gruchalla RS. Drug allergy. J Allergy Clin Immunol 2003; 111:548-559.
2. Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, editor. Textbook of adverse drug reactions. New York: Oxford University Press; 1991. pp. 18-45.
3. Levine BB. Immunologic mechanisms of penicillin allergy A haptenic model system for the study of allergic diseases of man. N Engl J Med 1966; 275:1115-1125.
4. Roujeau JC. Clinical Heterogeneity of drug hypersensitivity. Toxicology 2005; 209:123-129. This is an important review that highlights the important number of clinical manifestations in cutaneous adverse reactions to drug with immunological basis and mechanism heterogeneity.
5. Romano A, Blanca M, Torres MJ, et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy 2004; 59:1153-1160.
6. Park BK, Naisbitt DJ, Gordon SF, et al. Metabolic activation inn drug allergies. Toxicology 2001; 158:11-23.
7. Friedmann PS, Leew MS, Friedmannw AC, Barnetsonw RC. Mechanisms in cutaneous drug hypersensitivity reactions. Clin Exp Allergy 2003; 33:861-872.
8. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for drug hypersensitivity reactions. In: Coombs RRA, Gells PGH, editors. Clinical aspects of immunology, 2nd ed. Philadelphia: Davis; 1968. pp. 575-596.
9. Brockow K, Romano A, Blanca M, Ring J, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45-51.
10. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209:209-216.
11. Hertl M, Merk HF. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995; 105:95S-98S.
12. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683-693.
13. Landsteiner K, Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61:643-656.
14. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004; 113:395-400.
15. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunoldkjdot 2002; 23:445-449.
16. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
17. Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30:847-855.
18. Blanca M, Posadas S, Torres MJ, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with nonimmediate cutaneous allergic drug reactions. Allergy 2000; 55:998-1004.
19. Zanni MP, Mauri-Hellweg D, Brander C, et al. Characterization of lidocaine-specific T cells. J Immunol 1997; 158:1139-1148.
20. Annunziato F, Sampognaro S, Campi P, et al. Highly Th2-skewed cytokine profile of betalactam-specific T cells from nonatopic subjects with adverse-drug reactions. J Immunol 1999; 163:1053-1059.
21. Mizukawa Y, Yamazaki Y, Teraki Y, et al. Direct evidence for interferonγ production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in Fixed Drug Eruption. Am J Pathol 2002; 161:1337-1347.
22. Padial MA, Alvarez-Ferreira J, Tapia B, et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol 2004; 150:139-142.
23. Schaerli P, Britschgi M, Keller M, et al. Characterization of human T cells that regulate neutrophilic skin inflammation. J Immunol 2004; 173:2151-2158.
24. Schmid S, Kuechler PC, Britschgi M, et al. Acute generalised exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002; 161:2079-2086.
25. Britschgi M, Steiner UC, Schmid S, et al. T cell involvement in drug-induced acute generalised exanthematous pustulosis. J Clin Invest 2001; 107:1433-1441.
26. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-493.
27. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-1215.
28. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129:466-468.
29. Mayorga C, Torres MJ, Corzo JL, et al. Improvement of toxic epidermal necrolysis after the early administration of a single high dose of intravenous immunoglobulin. Ann Allergy Asthma Immunol 2003; 91:86-91.
30. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in Toxic Epidermal Necrolysis. J Invest Dermatol 2004; 123:850-855.
31. Santamaría Babi LF, Moser R, Perez-Soler MT, et al. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1). J Immunol 1995; 154:1543-1550.
32. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990; 136:1053-1068.
33. Leyva L, Torres MJ, Posadas S, et al. Anticonvulsant induced toxic epidermal necrolysis: Monitoring the immunological response. J Allergy Clin Immunol 2000; 105:157-165.
34. Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001; 1:305-310.
35. Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. Allergy Clin Immunol 2000; 106:1171-1176.
36. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998; 139:1026-1032.
37. Castell JV. Allergic Hepatitis: a drug-mediated organ-specific immune reaction. Clin Exp Allergy 1998; 28:13-19.
38. Maria VAJ, Victorino RMM. Immunological investigation in hepatic drug reactions. Clin Exp Allergy 1998; 28:71-77.
39. Luque I, Leyva L, Torres MJ, et al. In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions. Allergy 2001; 56:611-618.
40. Moser B. Chemokines: role in immune cell traffic. Eur Cytokine Netw 2003; 14:204-210.
41. Posadas SJ, Leyva L, Torres MJ, et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000; 106:769-776.
42. Padovan E, von Greyerz S, Pichler WJ, Weltzien HU. Antigen-dependent and - independent IFN-γ Modulation by penicillins. J Immunol 1999; 162:1171-1177.
43. Gaspard I, Kerdine S, Pallardy M, Lebrec H. Quantitation of cytokine mRNA expression as an endpoint for prediction and diagnosis of xenobiotic-induced hypersensitivity reactions. Methods 1999; 19:64-70.
44. Brander C, Mauri-Hellweg D, Bettens F, et al. Heterogeneous T cell responses to P-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 155:2670-2673.
45. Lebrec H, Kerdine S, Gaspard I, Pallardy M. Th1:Th2 responses to drugs. Toxicology 2001; 158:25-29.
46. Mauri-Helweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995; 155:462-472.
47. Brugnolo F, Annunziato F, Sampognaro S, et al. Highly Th2-skewed cytokine profile of betalactam-specific T cells from subjects with adverse-drug reactions. J Immunol 1999; 163:1053-1059.
48. Reddy M, Eirikis E, Davis C, et al. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods 2004; 293:127-142.
49. Mascher B, Schlenke P, Seyfarth M. Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. J Immunol Methods 1999; 223:115-121.
50. Tapia B, Padial A, Sanchez-Sabate E, et al. Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions. J Allergy Clin Immunol 2004; 114:335-340.
51. Favre N, Bordmann G, Rudin W. Comparison of cytokine measurements using ELISA, ELIPOT and semi-quantitative RT-PCR. J Immunol Methods 1997; 204:57-66.
52. House RV. Cytokine measurement techniques for assessing hypersensitivity. Toxicology 2001; 158:51-58.
53. Brewer G. Misregulated posttranscriptional checkpoints: inflammation and tumorigenesis. J Exp Med 2001; 193:F1-F4.
54. Espel E, Garcia-Sanz JA, Aubert V, et al. Transcriptional and translational control of TNFa gene expression in human monocytes by major histocompatibility complex class II ligands. Eur J Immunol 1996; 26:2417-2424.
55. Bamford RN, DeFilippis AP, Azimi N, et al. The 5′untranslated region, signal peptide, and the coding sequence of the carboxy terminus of IL-15 participate in its multifaceted translational control. J Immunol 1998; 160:4418-4426.
56. Niwa Y, Akamatsu H, Sumi H, et al. Evidence for degradation of cytokines in the serumof patients with atopic dermatitis by calcium-dependent protease. Arch Dermatol Res 2000; 292:391-396.
57. Arvâ E, Andersson B. Kinetics of cytokine release and expression of lymphocyte cell-surface activation markers after in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae. Scand J Immunol 1999; 49:237-243.
58. Bachmann MF, Barner M, Viola A, Kopf M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur J Immunol 1999; 29:291-299.
59. Rostaing L, Tkaczuk J, Durand M, et al. Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by flow cytometry following in vitro activation of peripheral blood mononuclear cells. Cytometry 1999; 35:318-328.
60. Rioja I, Bush KA, Buckton JB, et al. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 2004; 137:65-73.
61. Stordeur P, Zhou L, Byl B, et al. Immune monitoring in whole blood using real-time PCR. J Immunol Methods 2003; 276:69-77.
62. Zimmermann C, Prevost-Blondel A, Blaser C, Pircher H. Kinetics of the response of naive and memory CD8 T cells to antigen: similarities and differences. Eur J Immunol 1999; 29:284-290.
63. Foster JR. The functions of cytokines and their uses in toxicology. Int J Exp Pathology 2001; 82:171-192.
64. Torres MJ, Mayorga C, Fernández TD, et al. T cell assessment in allergic drug reactions during the acute phase according to the time of occurrence. Int J Immunopathol Pharmacol 2006; 19:727-737.
65. Homey B, Alenius H, Muller A, et al. CCL27-CCR10 interactions regulate T cell mediated skin inflammation. Nat Med 2002; 8:157-165.
66. Soler D, Humphreys TL, Spinola SM, Campbell JJ. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 2003; 101:1677-1682.
67. Chong BF, Murphy JE, Jupper TS, Fuhlbrigge RC. E-selectine, thymus and activation-regulated chemokines/CCL17, and intracellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: a foundation for a cutaneous immunosurveillance system. J Immunol 2004; 172:1575-1581.
68. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25:75-81.